Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
Explore linked clinical trials.16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. | Moderate to Severe Genital Psoriasis | Active, not recruiting | Phase 3 | 2026-09-01 | NCT06611163 | |
| An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face | Skin and Connective Tissue Diseases, actinic keratosis, keratosis, neoplasm, precancerous condition, skin disorder | Recruiting | Phase 1 | 2026-08-13 | NCT07729579 | |
| Cardiovascular-Kidney-Metabolic Syndrome Registry | Body Weight, Chronic Disease, Disease Attributes, Dyslipidemias, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lipid Metabolism Disorders, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hyperlipidemia, hypertensive disorder, hypertriglyceridemia, kidney disorder, kidney failure, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus, urinary system disorder, vascular disorder | Not yet recruiting | Not stated | 2026-07-22 | NCT07718789 | |
| Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic malignant neoplasm, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-06-15 | NCT05422911 | |
| Psoriatic Immune Response to Tildrakizumab | Psoriasis Vulgaris | Recruiting | Phase 4 | 2026-06-04 | NCT05390515 | |
| A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis | Moderate-to-severe Chronic Plaque Psoriasis | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-15 | NCT03997786 | |
| Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-03-18 | NCT07282743 | |
| Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Recruiting | Phase 1 | 2026-03-13 | NCT07385547 | |
| Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | Active Psoriatic Arthritis | Active, not recruiting | Phase 3 | 2026-03-10 | NCT04314531 | |
| Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 3 | 2026-03-05 | NCT04991116 | |
| A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients | Acneiform Eruptions, Skin and Connective Tissue Diseases, acne, sebaceous gland disorder, skin disorder | Active, not recruiting | Phase 4 | 2026-01-21 | NCT06425900 | |
| Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab | Pregnancy Related | Recruiting | Not stated | 2026-01-21 | NCT03992729 | |
| Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma | Neoplasms by Histologic Type, basal cell carcinoma, basal cell neoplasm, carcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2025-09-30 | NCT05561634 | |
| Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea | Papulopustular Rosacea, Skin and Connective Tissue Diseases, rosacea, skin disorder | Recruiting | Phase 2 | 2025-05-06 | NCT06952517 | |
| Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study | Abnormalities, Multiple, Bone Diseases, Developmental, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cysts, Jaw Cysts, Jaw Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Stomatognathic Diseases, basal cell carcinoma, basal cell neoplasm, bone disorder, carcinoma, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, musculoskeletal system disorder, neoplasm, nevoid basal cell carcinoma syndrome, odontogenic cyst, skin disorder, skin neoplasm, solitary bone cyst | Recruiting | Not stated | 2025-04-04 | NCT05463757 | |
| ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis. | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Recruiting | Phase 4 | 2020-04-15 | NCT04347473 |